drugset / Trial / NCT03150004

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

NCT03150004

Phase 2 Terminated 53 enrolled Medical College of Wisconsin
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen and followed at periodic intervals to determine the primary and secondary objectives.

Timeline

Start
2017-06-14
Primary completion
2025-03-14
Completion
2025-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Cladribine Small molecule 5 mg/m2 Intravenous
Subject Cytarabine Small molecule 20 mg/m2 Intravenous
Subject Cytarabine Small molecule 2 g Intravenous
Subject Mitoxantrone Small molecule 10 mg/m2 Intravenous
Background G-CSF Unknown 300 ug